Patent ID: 11872195
Assignee: FRED HUTCHINSON CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of selectively modifying a selected cell population of hematopoietic origin in vivo, the method comprising:
i) adding 12 kDa to 18 kDa polyglutamic acid (PGA) conjugated to selected cell targeting ligands that bind the selected cell population of hematopoietic origin to a first solution comprising nucleic acid encapsulated within poly(β-amino ester) (PBAE) to form a second solution; and
ii) incubating the second solution wherein selected cell-targeted synthetic nanocarriers form within 5 minutes of the adding and comprise
A) the nucleic acid encapsulated within the PBAE;
B) a coating comprising the PGA on the outer surface of the PBAE; and
C) the selected cell targeting ligands extending from the outer surface of the coating and conjugated to the PGA within the coating; and

iii) administering the formed selected cell-targeted synthetic nanocarriers to a subject comprising the selected cell population of hematopoietic origin, thereby selectively modifying the selected cell population of hematopoietic origin in vivo.